ShEEP Request for Imaging Mass Cytometry

ShEEP 成像质量细胞计数请求

基本信息

  • 批准号:
    9905867
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-09-01 至 2020-09-30
  • 项目状态:
    已结题

项目摘要

The goal of this proposal is to install and integrate the Fluidigm Hyperion Imaging Mass Cytometer (IMC) system in the Cellular and Molecular Evaluation Core (CMEC) Facility within Research Service at the Ralph H. Johnson (RHJ) VA Medical Center. The overarching objective of this core facility is to provide tools and services, including immunohistochemical, flow cytometry, and cell sorting applications, necessary to support and advance research that directly impacts the health of our Veterans. Conventional immunohistochemical (IHC) approaches have been historically limited to the simultaneous detection of only a few markers (~8). Traditional flow cytometry, while allowing for multiparameter analysis, does not allow for spatial analysis of cellular or subcellular marker expression within a tissue. In contrast, time of flight mass cytometry (CyTOF) allows for the simultaneous detection of 40+ markers on one single cell. By combining the existing high dimensional Helios mass cytometer CyTOF platform with the Hyperion laser ablation system, we are able to bring this powerful detection method, termed imaging mass cytometry (IMC), into tissues. The central hypothesis addressed by this core is that the high dimensional analysis Hyperion IMC system will allow VA researchers to use small fixed tissue samples to examine complex subcellular, cellular, and cell-matrix interactions in the intact tissue microenvironment and provide a technology bridge to existing transcriptomic and imaging methods to understand pathologies impacting our Veterans. Our investigators have identified four primary aims that will be accomplished through this groundbreaking technology that provides high throughput, high-dimensional quantitative analyses in situ of complex cellular samples: 1) Identify novel cell types and their cellular and sub-cellular proteins that contribute to the pathology of disease; 2) Uncover new intracellular, cell- cell, and cell-ECM interactions important for disease progression; 3) Examine rare events (including stem cells) in physiological and pathological conditions; and 4) Discover novel biomarkers of disease and/or clinical response to treatment, enhancing the development of targeted, personalized, precision therapies. The state-of-the-art technology afforded by the Hyperion IMC System is broadly applicable across the diverse animal- and human-based research efforts of our local VAMC investigators including studies in traumatic brain injury, stroke, spinal cord injury, respiratory illness, cardiovascular disease, immunology, oncology, orthopedic injury, Alzheimer’s disease, and mental health disorders. This technology does not currently exist at RHJ VAMC, the Affiliate (Medical University of South Carolina, MUSC), or in the state. Based on the number of interested investigators and diverse disease-related applications, we believe that this upgrade will meet demands of investigators for cutting edge technologies to advance translational medicine and allow the VA CMEC to provide the next generation of mass cytometry capabilities. This expansion will position VA as a leader in integration of mass cytometry into clinical trials, personalized disease treatments, and development of novel therapies. Incorporating the Hyperion Imaging Mass Cytometer System into the established CMEC will greatly strengthen the research capabilities of our station (and those in the VISN), facilitating basic scientific discovery of mechanisms underlying physiological and pathological processes and translation of these findings to support the rapid implementation of cutting-edge personalized medical treatment to improve quality healthcare for our Nation’s Veterans.
该计划的目标是安装和集成Fluidigm Hyperion成像质量细胞仪(IMC)系统 在拉尔夫·H·约翰逊研究所的细胞和分子评估核心(CMEC)设施中 (RHJ)退伍军人医疗中心这一核心设施的总体目标是提供工具和服务,包括 支持和推进研究所必需的免疫组织化学、流式细胞术和细胞分类应用 这直接影响到我们退伍军人的健康。传统的免疫组织化学(IHC)方法 历史上仅限于同时检测几个标记(~8个)。传统的流式细胞术, 虽然允许多参数分析,但不允许对细胞或亚细胞标记进行空间分析 在组织中的表达。相比之下,飞行时间质量细胞术(CyTOF)允许同时 在单个细胞上检测40+个标记。通过结合现有的高维Helios质量细胞仪 CyTOF平台配合Hyperion激光消融系统,我们能够带来这种强大的检测方法, 被称为成像质量细胞术(IMC),进入组织。 这个核心提出的中心假设是,高维分析Hyperion IMC系统将 允许退伍军人事务部研究人员使用小的固定组织样本来检查复杂的亚细胞、细胞和细胞基质 在完整的组织微环境中的相互作用,并提供了一座连接到现有转录和 了解影响退伍军人的病理的成像方法。我们的调查人员已经确认了四个 将通过这一突破性技术实现的主要目标是提供高吞吐量、 复杂细胞样本的高维原位定量分析:1)识别新的细胞类型和它们的 有助于疾病病理的细胞和亚细胞蛋白质;2)发现新的细胞内、细胞- 细胞、细胞与细胞外基质的相互作用对疾病进展很重要;3)检查罕见事件(包括干细胞) 在生理和病理条件下;以及4)发现疾病和/或临床的新生物标志物 应对治疗,促进有针对性、个性化、精准治疗的发展。 Hyperion IMC系统提供的最先进技术广泛适用于各种 我们当地VAMC研究人员的动物和人类研究努力,包括对创伤性脑的研究 损伤、中风、脊髓损伤、呼吸系统疾病、心血管疾病、免疫学、肿瘤学、骨科 伤害、阿尔茨海默氏症和精神健康障碍。这项技术目前在RHJ VAMC中不存在, 附属机构(南卡罗来纳医科大学,MUSC),或在该州。根据感兴趣的人数 调查人员和多样化的疾病相关应用,我们相信这次升级将满足 尖端技术的调查人员推动转化医学,并允许退伍军人事务部提供 下一代的质量细胞仪能力。这一扩展将使退伍军人管理局成为整合 将质量细胞术应用于临床试验、个性化疾病治疗和新疗法的开发。 将Hyperion成像质量细胞仪系统纳入已建立的CMEC将大大加强 我们空间站(和VISN的研究能力)的研究能力,促进了基础科学发现 生理和病理过程的潜在机制以及这些发现的翻译支持 快速实施尖端个性化医疗,提高我国医疗质量 国家的退伍军人。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

AMANDA C. LARUE其他文献

AMANDA C. LARUE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('AMANDA C. LARUE', 18)}}的其他基金

Exposing Invisible Wounds: Impacts of PTSD on Bone Health
暴露看不见的伤口:创伤后应激障碍 (PTSD) 对骨骼健康的影响
  • 批准号:
    10481895
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Targeting HSC-derived Circulating Fibroblast Precursors in Pulmonary Fibrosis
靶向 HSC 衍生的循环成纤维细胞前体治疗肺纤维化
  • 批准号:
    8582197
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Targeting HSC-derived Circulating Fibroblast Precursors in Pulmonary Fibrosis
靶向 HSC 衍生的循环成纤维细胞前体治疗肺纤维化
  • 批准号:
    8764634
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Targeting HSC-derived Circulating Fibroblast Precursors in Pulmonary Fibrosis
靶向 HSC 衍生的循环成纤维细胞前体治疗肺纤维化
  • 批准号:
    9275406
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Targeting HSC-derived Circulating Fibroblast Precursors in Pulmonary Fibrosis
靶向 HSC 衍生的循环成纤维细胞前体治疗肺纤维化
  • 批准号:
    8966667
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Hematopoietic Stem Cell-Derived Carcinoma Associated Fibroblasts in Tumor
肿瘤中造血干细胞衍生的癌相关成纤维细胞
  • 批准号:
    8607154
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Hematopoietic Stem Cell-Derived Carcinoma Associated Fibroblasts in Tumor
肿瘤中造血干细胞衍生的癌相关成纤维细胞
  • 批准号:
    8217145
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Hematopoietic Stem Cell-Derived Carcinoma Associated Fibroblasts in Tumor
肿瘤中造血干细胞衍生的癌相关成纤维细胞
  • 批准号:
    8433442
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Hematopoietic Stem Cell-Derived Carcinoma Associated Fibroblasts in Tumor
肿瘤中造血干细胞衍生的癌相关成纤维细胞
  • 批准号:
    8040183
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Potential of Hematopoietic Stem Cell-Based Therapies for Complicated Fractures
基于造血干细胞的复杂骨折疗法的潜力
  • 批准号:
    10045563
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了